The efficacy of brimonidine in decreasing elevations in intraocular pressure after laser trabeculoplasty

H. S. Barnebey, Alan L. Robin, T. J. Zimmerman, J. C. Morrison, S. B. Hersh, R. A. Lewis, A. L. Coleman, D. J. Cinotti, J. Walt, K. S. Chen, E. P. Kelley

Research output: Contribution to journalArticle

Abstract

Purpose: The authors explored the empirical dosing requirement for administration of an α2-adrenoceptor agonist, brimonidine, and determined its efficacy in decreasing elevations in intraocular pressure (IOP) after 360° argon laser trabeculoplasty (ALT). Methods: This vehicle-controlled, double-masked, multicenter trial evaluated three dosing regimens of brimonidine. Two hundred thirty-two patients for whom 360° ALT was indicated were randomized into one of four treatment groups: 0.5% brimonidine both before and after ALT; brimonidine before but vehicle after ALT; vehicle before but brimonidine after ALT; or vehicle at both times. Results: During the first 3 hours after 360° ALT, the overall incidence of IOP elevations of 5 mmHg or greater was 38% (23 of 60 eyes) in the group receiving vehicle only, and it ranged from 3% to 9% (2 of 62 to 5 of 53 eyes) in the groups receiving any brimonidine treatment. There was little difference in efficacy between the three dosing regimens of brimonidine. Brimonidine was well tolerated by the patients. Conclusion: Based on this large, controlled, multicenter study, 0.5% brimonidine was an effective agent for reducing elevations in IOP after 360° ALT. Only one dose, administered either before or after 360° ALT, was required.

Original languageEnglish (US)
Pages (from-to)1083-1088
Number of pages6
JournalOphthalmology
Volume100
Issue number7
StatePublished - 1993

Fingerprint

Trabeculectomy
Argon
Intraocular Pressure
Lasers
Multicenter Studies
Brimonidine Tartrate
Reducing Agents
Adrenergic Receptors
Incidence

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Barnebey, H. S., Robin, A. L., Zimmerman, T. J., Morrison, J. C., Hersh, S. B., Lewis, R. A., ... Kelley, E. P. (1993). The efficacy of brimonidine in decreasing elevations in intraocular pressure after laser trabeculoplasty. Ophthalmology, 100(7), 1083-1088.

The efficacy of brimonidine in decreasing elevations in intraocular pressure after laser trabeculoplasty. / Barnebey, H. S.; Robin, Alan L.; Zimmerman, T. J.; Morrison, J. C.; Hersh, S. B.; Lewis, R. A.; Coleman, A. L.; Cinotti, D. J.; Walt, J.; Chen, K. S.; Kelley, E. P.

In: Ophthalmology, Vol. 100, No. 7, 1993, p. 1083-1088.

Research output: Contribution to journalArticle

Barnebey, HS, Robin, AL, Zimmerman, TJ, Morrison, JC, Hersh, SB, Lewis, RA, Coleman, AL, Cinotti, DJ, Walt, J, Chen, KS & Kelley, EP 1993, 'The efficacy of brimonidine in decreasing elevations in intraocular pressure after laser trabeculoplasty', Ophthalmology, vol. 100, no. 7, pp. 1083-1088.
Barnebey HS, Robin AL, Zimmerman TJ, Morrison JC, Hersh SB, Lewis RA et al. The efficacy of brimonidine in decreasing elevations in intraocular pressure after laser trabeculoplasty. Ophthalmology. 1993;100(7):1083-1088.
Barnebey, H. S. ; Robin, Alan L. ; Zimmerman, T. J. ; Morrison, J. C. ; Hersh, S. B. ; Lewis, R. A. ; Coleman, A. L. ; Cinotti, D. J. ; Walt, J. ; Chen, K. S. ; Kelley, E. P. / The efficacy of brimonidine in decreasing elevations in intraocular pressure after laser trabeculoplasty. In: Ophthalmology. 1993 ; Vol. 100, No. 7. pp. 1083-1088.
@article{73d85486e8c64b80a90ff01d7d68e3fa,
title = "The efficacy of brimonidine in decreasing elevations in intraocular pressure after laser trabeculoplasty",
abstract = "Purpose: The authors explored the empirical dosing requirement for administration of an α2-adrenoceptor agonist, brimonidine, and determined its efficacy in decreasing elevations in intraocular pressure (IOP) after 360° argon laser trabeculoplasty (ALT). Methods: This vehicle-controlled, double-masked, multicenter trial evaluated three dosing regimens of brimonidine. Two hundred thirty-two patients for whom 360° ALT was indicated were randomized into one of four treatment groups: 0.5{\%} brimonidine both before and after ALT; brimonidine before but vehicle after ALT; vehicle before but brimonidine after ALT; or vehicle at both times. Results: During the first 3 hours after 360° ALT, the overall incidence of IOP elevations of 5 mmHg or greater was 38{\%} (23 of 60 eyes) in the group receiving vehicle only, and it ranged from 3{\%} to 9{\%} (2 of 62 to 5 of 53 eyes) in the groups receiving any brimonidine treatment. There was little difference in efficacy between the three dosing regimens of brimonidine. Brimonidine was well tolerated by the patients. Conclusion: Based on this large, controlled, multicenter study, 0.5{\%} brimonidine was an effective agent for reducing elevations in IOP after 360° ALT. Only one dose, administered either before or after 360° ALT, was required.",
author = "Barnebey, {H. S.} and Robin, {Alan L.} and Zimmerman, {T. J.} and Morrison, {J. C.} and Hersh, {S. B.} and Lewis, {R. A.} and Coleman, {A. L.} and Cinotti, {D. J.} and J. Walt and Chen, {K. S.} and Kelley, {E. P.}",
year = "1993",
language = "English (US)",
volume = "100",
pages = "1083--1088",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - The efficacy of brimonidine in decreasing elevations in intraocular pressure after laser trabeculoplasty

AU - Barnebey, H. S.

AU - Robin, Alan L.

AU - Zimmerman, T. J.

AU - Morrison, J. C.

AU - Hersh, S. B.

AU - Lewis, R. A.

AU - Coleman, A. L.

AU - Cinotti, D. J.

AU - Walt, J.

AU - Chen, K. S.

AU - Kelley, E. P.

PY - 1993

Y1 - 1993

N2 - Purpose: The authors explored the empirical dosing requirement for administration of an α2-adrenoceptor agonist, brimonidine, and determined its efficacy in decreasing elevations in intraocular pressure (IOP) after 360° argon laser trabeculoplasty (ALT). Methods: This vehicle-controlled, double-masked, multicenter trial evaluated three dosing regimens of brimonidine. Two hundred thirty-two patients for whom 360° ALT was indicated were randomized into one of four treatment groups: 0.5% brimonidine both before and after ALT; brimonidine before but vehicle after ALT; vehicle before but brimonidine after ALT; or vehicle at both times. Results: During the first 3 hours after 360° ALT, the overall incidence of IOP elevations of 5 mmHg or greater was 38% (23 of 60 eyes) in the group receiving vehicle only, and it ranged from 3% to 9% (2 of 62 to 5 of 53 eyes) in the groups receiving any brimonidine treatment. There was little difference in efficacy between the three dosing regimens of brimonidine. Brimonidine was well tolerated by the patients. Conclusion: Based on this large, controlled, multicenter study, 0.5% brimonidine was an effective agent for reducing elevations in IOP after 360° ALT. Only one dose, administered either before or after 360° ALT, was required.

AB - Purpose: The authors explored the empirical dosing requirement for administration of an α2-adrenoceptor agonist, brimonidine, and determined its efficacy in decreasing elevations in intraocular pressure (IOP) after 360° argon laser trabeculoplasty (ALT). Methods: This vehicle-controlled, double-masked, multicenter trial evaluated three dosing regimens of brimonidine. Two hundred thirty-two patients for whom 360° ALT was indicated were randomized into one of four treatment groups: 0.5% brimonidine both before and after ALT; brimonidine before but vehicle after ALT; vehicle before but brimonidine after ALT; or vehicle at both times. Results: During the first 3 hours after 360° ALT, the overall incidence of IOP elevations of 5 mmHg or greater was 38% (23 of 60 eyes) in the group receiving vehicle only, and it ranged from 3% to 9% (2 of 62 to 5 of 53 eyes) in the groups receiving any brimonidine treatment. There was little difference in efficacy between the three dosing regimens of brimonidine. Brimonidine was well tolerated by the patients. Conclusion: Based on this large, controlled, multicenter study, 0.5% brimonidine was an effective agent for reducing elevations in IOP after 360° ALT. Only one dose, administered either before or after 360° ALT, was required.

UR - http://www.scopus.com/inward/record.url?scp=0027231501&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027231501&partnerID=8YFLogxK

M3 - Article

VL - 100

SP - 1083

EP - 1088

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

IS - 7

ER -